Masayoshi Toyoura

This inventor holds 5 USPTO granted patents and 5 published patent applications and 2 EPO patents. Top assignees: Pharma Foods International Co., Ltd., Kochi University, Public University Corporation Nagoya City University. Active years: 2018-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Masayoshi Toyoura. Retrieved from https://idiyas.com/inventor/masayoshi-toyoura

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 5 (Patent Applications = 5)

% Patents Active = 100.0

EPO Patents = 2 (Patent Applications = 5)

Average Co-Inventor Count = 5.6

ph-index = 1

Forward Citations = 6(Granted Patents)

Company Filing History:

3 out of 10

Pharma Foods International Co., Ltd.

Public University Corporation Nagoya City University

patents

4. 2 out of 57

Yokohama City University

patents

where one patent can have more than one assignee

Years Active: 2018-2025

Loading Chart...

5 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12448464 - Anti-PAD4 antibody (2025-10-21),

2. 11447569 - Anti-PAD4 antibody (2022-09-20),

3. 10806787 - Anticancer agents or antimetastatic agents using FSTL1 and combination drug thereof (2020-10-20),

4. 10174111 - Therapeutic drug for malignant tumors (2019-01-08),

5. 10077316 - Esophageal cancer marker and use thereof (2018-09-18),

Title: Masayoshi Toyoura: Innovator in Anti-PAD4 Antibodies

Introduction

Masayoshi Toyoura is a prominent inventor based in Kyoto, Japan. He has made significant contributions to the field of biotechnology, particularly in the development of anti-PAD4 antibodies. With a total of 5 patents to his name, Toyoura's work is paving the way for innovative treatments in rheumatoid arthritis (RA).

Latest Patents

Toyoura's latest patents focus on anti-PAD4 antibodies that exhibit excellent properties for the treatment of RA. These antibodies specifically bind to an epitope containing positions 345, 347, and 348 of PAD4. They are designed to inhibit the citrullination activity of PAD4, which is crucial in the pathology of RA. Additionally, these anti-PAD4 antibodies may have a KD (M) of 9.0×10 or less. In some cases, the anti-PAD4 antibody is used in combination with a TNFα inhibitor to enhance therapeutic efficacy.

Career Highlights

Throughout his career, Masayoshi Toyoura has worked with notable organizations such as Pharma Foods International Co., Ltd. and Kochi University. His research and innovations have significantly impacted the field of immunology and therapeutic development.

Collaborations

Some of Toyoura's key collaborators include Yuji Shoya and Chihiro Yamazaki. Their combined expertise has contributed to the advancement of research in antibody development.

Conclusion

Masayoshi Toyoura's innovative work in the field of anti-PAD4 antibodies represents a significant advancement in the treatment of rheumatoid arthritis. His contributions continue to inspire future research and development in biotechnology.

Profile summary based on public USPTO records.